Arboviruses continue to pose serious public health threats in the World Health Organization (WHO) Western Pacific Region. As such, laboratories need to be equipped for their accurate detection. In 2011, to ensure test proficiency, the WHO Regional Office for the Western Pacific piloted an external quality assessment (EQA) programme for arbovirus diagnostics. By 2016, it had grown into a global programme with participation of 96 laboratories worldwide, including 25 laboratories from 19 countries, territories and areas in the Region. The test performance of the 25 laboratories in the Region in 2016 was high with 23 (92%) reporting correct results in all specimens for dengue and chikungunya viruses. For Zika virus, 18 (72%) of the 25 laboratories reported correct results in all specimens, while seven (28%) demonstrated at least one error. When comparing iterations of this EQA programme in the Region between 2013 and 2016, the number of participating laboratories increased from 18 to 25. The first round only included dengue virus, while the latest round additionally included chikungunya, Zika and yellow fever viruses. Proficiency for molecular detection of dengue virus remained high (83–94%) over the four-year period. The observed proficiency for arbovirus diagnostics between 2013 and 2016 is an indicator of laboratory quality improvement in the Region.

Arboviruses continue to pose a serious threat to human health worldwide as evidenced by the emergence and re-emergence of arboviral infections in the form of outbreaks globally in the last five years. During this time, the world witnessed the re-emergence of chikungunya virus (CHIKV) and Zika virus (ZIKV) while dengue virus (DENV) and yellow fever virus (YFV) continued to circulate widely. In February 2016, the Director-General of the World Health Organization (WHO) declared a Public Health Emergency of International Concern (PHEIC) in response to ZIKV, microcephaly and other neurological disorders reported in Brazil, following a similar cluster in French Polynesia in 2014. This declaration ended in November 2016 in favour of a longer-term programmatic approach.

The WHO Western Pacific Region bears a large arboviral disease burden. For dengue alone, there were more than 860 000 cases and 1500 deaths reported between 2013 and 2016 (WHO Regional Office for the Western Pacific, unpublished data, 2017). CHIKV is endemic in the Region and considered a threat to the Pacific island countries and areas with recent outbreaks in New Caledonia and Papua New Guinea. The first recorded outbreak of ZIKV disease in the Region was in the Federated States of Micronesia in 2007. The virus has since been detected in the majority of the countries and occasionally causes outbreaks such as in Singapore in 2016.

Preparedness in the face of such potential disease occurrences is paramount. Therefore, public health laboratories and their equivalent in the research sector throughout the Region have developed or adopted molecular methods for arbovirus detection. These new assays complement serological assays already in use and allow for diagnosis in the early stages of illness. To assess the competency of laboratories in the Region, an external quality assessment (EQA) programme for arbovirus diagnostics was developed in 2011 with the goal of enabling the laboratories to gauge their proficiency and to identify areas for improvement. While test capacity is an indication of whether laboratories have the necessary elements, including required equipment,
reagents and protocols in place to perform a test and to
gauge the throughput, proficiency relates to how reliably
and accurately a test is performed. The establishment
of an EQA programme for dengue diagnostics was part
of the Asia Pacific Strategy for Emerging Diseases
(2010), an action framework for building International
Health Regulations core capacities. Participation in
EQA programmes is a requirement for achieving the
International Organization for Standardization 15189
accreditation, which specifies the quality management
system requirements particular to medical laboratories.

The development of the EQA programme involved
the main reference laboratories and collaborating centres
in the Region (Fig. 1). A pilot to assess the feasibility,
including panel preparation and logistics, of EQA for
dengue diagnostics was first conducted by the National
Institute of Infectious Diseases, Japan in 2011. This
informed the development of the first round of EQA
for dengue, which was introduced in 2013. Eighteen
laboratories participated in the programme, which was
coordinated by the Environmental Health Institute (EHI),
Singapore, a WHO Collaborating Centre for Reference and
Research of Arbovirus and their Associated Vectors. There
was no round of EQA in 2014 due to logistic and technical
review of the first round for improvement of subsequent
iterations. In 2015, a second round of EQA, not only for
dengue but also chikungunya diagnostics, was prepared
by EHI and involved 24 laboratories, including 19 in the
Region and five in the WHO South-East Asia Region. In
2016, in succession to the two regional programmes,
WHO organized the first global EQA programme for
arbovirus diagnostics. The programme was developed
and managed by the Royal College of Pathologists of
Australasia Quality Assurance Programs. As of July 2017,
global participation stands at 96 laboratories throughout
all WHO regions.

In 2016, 26 laboratories in the Region were invited
to participate in the EQA programme. This iteration of
the EQA assessed participating laboratories’ capacity and
proficiency for DENV, CHIKV, ZIKV and YFV (optional)
diagnosis by polymerase chain reaction (PCR). Panels
containing blinded samples of various dilutions of the four
arboviruses to be identified by participating laboratories
were shipped between November and December 2016.
Of the 26 laboratories invited, 25 laboratories from 19
countries, territories and areas in the Region returned
results; one laboratory was unable to participate due
to logistical issues preventing delivery of the panel. All
25 laboratories participated in PCR diagnosis of the
three required viruses; additionally, 22 performed DENV
serotyping and 13 participated in the optional YFV
component of the EQA. Results from the 2016 EQA are
presented in Fig. 2.

In 2016, test performance was high with 23 of
25 (92%) laboratories reporting correct results in all
specimens in the panel for DENV and CHIKV. For ZIKV,
18 (72%) laboratories reported correct results in all
specimens, while seven (28%) demonstrated at least one
error. Twenty-one of 22 (95%) laboratories were able to
correctly identify DENV serotypes. All four laboratories
that performed ZIKV lineage testing correctly determined
whether the strain was of Asian or African lineage.
Overall, errors appeared to be randomly distributed,
and no patterns of inaccuracy could be observed for
particular specimens or laboratories (data not shown). Of
the 13 laboratories that took part in the optional module
for detection of YFV, nine (69%) successfully identified
YFV in test specimens. While not endemic or reported
in Asia, demonstrating regional preparedness to detect
and confirm YFV is vital in the event an outbreak were
to occur. The importance of having diagnostic capacity
for YFV was highlighted by the recent importations of
laboratory-confirmed YFV cases from Angola into China.

A laboratory preparedness survey to determine test
capacity for arboviruses in the Region was conducted
in February 2016, immediately after the declaration of
a PHEIC related to ZIKV. It revealed that of the 19
national-level public health laboratories surveyed, 16
(84%) reported molecular testing capacity for ZIKV. The
results of the 2016 EQA for arboviruses indicate that, in
addition to test capacity, laboratories have a high level
of test proficiency for ZIKV. Additionally, three countries
that indicated not having test capacity at the time of the
survey had this capacity in place at the time of the 2016
EQA (data not shown).

When comparing the results of the EQA programmes
in the Region between 2013 and 2016, EQA participation
has consistently increased since 2013 (Fig. 2). Laboratories
in the Region demonstrated good proficiency at detecting
DENV in 2013 and both DENV and CHIKV in 2015 with
more than 83% of laboratories reporting correct results
for all specimens in the panels. The Region can now claim
at least 23 national-level public health laboratories with
Improving laboratory quality in the Western Pacific Region (2013–2016) Abdad et al

Fig. 1. Increase in the number of participating laboratories, geographic coverage and variety of pathogens of the WHO EQA programme for arbovirus diagnostics from pilot to global programme, 2011–2016

Legend: Evolution of the EQA programme for arbovirus diagnostics from 2011 to 2016 showing an increase in number of participating laboratories, geographic coverage and variety of pathogens included. No round of EQA was conducted in 2014. Circles and their relative size provide an illustration of this growth over time and by WHO region. Numbers under respective region or global indicate number of participating laboratories. Pathogens included in each panel are listed inside each circle. CHIKV = chikungunya virus; DENV = dengue virus; Global (red); SEAR = South-East Asia Region (green); WPR = Western Pacific Region (dark blue); YFV = yellow fever virus; and ZIKV = Zika virus.

Fig. 2. Proficiency* of laboratories in the WHO Western Pacific Region participating in the EQA programme for arbovirus diagnostics, 2013–2016

Legend: CHIKV = chikungunya virus; DENV = dengue virus; YFV = yellow fever virus; and ZIKV = Zika virus.

*Proficiency is defined as the percentage of laboratories reporting all correct results for a component of the EQA panel. No round of EQA was conducted in 2014.
consistently high accurate molecular detection capacity for DENV and CHIKV compared to previous years. The observed increase in participation and improvements in EQA results suggest that laboratory managers are continuously improving their laboratory operations. Their commitment is important in making sure that the Region is prepared for health emergencies, supporting routine surveillance and providing accurate diagnoses.

The EQA programme is an evolving tool that will continue to be reviewed and changed to monitor and inform improvement of laboratory diagnostic testing for arboviral diseases. It shows that small initiatives can grow into larger accomplishments in a stepwise manner when sufficient investments are made and when the impact on public health by better surveillance and response is recognized. The observation of an increasing number of participants and high proficiency between 2013 and 2016 is an indicator of improvement in laboratory capacity and performance in the Region.

Conflicts of interest

None declared.

Funding

The regional and global programmes were supported by the United States Agency for International Development, the Centers for Disease Control and Prevention, and the Global Partnership Program of Global Affairs Canada.

Acknowledgements

The authors are grateful to the laboratories that participated in the development of the EQA programme for arboviruses over the years since 2011. They would also like to thank all the national-level public health and research laboratories that participated in the EQA programme since its roll-out in 2013.

References

1. WHO Director-General summarizes the outcome of the Emergency Committee meeting regarding clusters of microcephaly and Guillain-Barre syndrome. Geneva: World Health Organization; 2016 (http://www.who.int/mediacentre/news/statements/2016/emergency-committee-zika-microcephaly/en/, accessed 24 May 2017).

2. Fifth meeting of the Emergency Committee under the International Health Regulations (2005) regarding microcephaly, other neurological disorders and Zika virus. Geneva: World Health Organization; 2016 (http://www.who.int/mediacentre/news/statements/2016/zika-fifth-ec/en/, accessed 24 May 2017).

3. Horwood P, Bande G, Dagina R, Guillaumot L, Aaskov J, Pavlin B. The threat of chikungunya in Oceania. West Pac Surveill Response. 2013 06 04;4(2):8–10. pmid:24015365 doi:10.5365/wpsar.2013.4.2.003

4. Duffy MR, Chen TH, Hancock WT, Powers AM, Kool JL, Lanciotti RS, et al. Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009 Jun 11;360(24):2536–43. pmid:19516034 doi:10.1056/NEJMoa0805715

5. Ho ZJM, Hapuarachchi HC, Barkham T, Chow A, Ng LC, Lee JMV, et al.; Singapore Zika Study Group. Outbreak of Zika virus infection in Singapore: an epidemiological, entomological, virological, and clinical analysis. Lancet Infect Dis. 2017 Aug;17(8):813–21. pmid:28527892 doi:10.1016/S1473-3099(17)30249-9

6. Asia Pacific Strategy for Emerging Diseases, 2010. Manila: World Health Organization Regional Office for the Western Pacific; 2011 (http://www.wpro.who.int/emerging_diseases/documents/docs/ASPED_2010.pdf?ua=1, accessed 24 May 2017).

7. ISO 15189:2012. Medical laboratories – requirements for quality and competence. Geneva: International Organization for Standardization, 2012.

8. Pok KY, Squires RC, Tan LK, Takasaki T, Abubakar S, Hasebe F, et al. First round of external quality assessment of dengue diagnostics in the WHO Western Pacific Region, 2013. West Pac Surveill Response. 2015 06 30;6(2):73–81. pmid:26306220 doi:10.5365/wpsar.2015.6.1.017

9. Soh LT, Squires RC, Tan LK, Pok KY, Yang H, Liew C, et al. External quality assessment of dengue and chikungunya diagnostics in the Asia Pacific region, 2015. West Pac Surveill Response. 2016 04 22;7(2):26–34. pmid:27508088 doi:10.5365/wpsar.2016.7.1.002

10. Yellow fever – China, Disease Outbreak News, 22 April 2016. Geneva: World Health Organization; 2016 (http://www.who.int/csr/don/22-april-2016-yellow-fever-china/en/, accessed 24 May 2017).

11. Squires RC, Konings F; World Health Organization Regional Office for the Western Pacific Zika Incident Management Team. Preparedness for Zika virus testing in the World Health Organization Western Pacific Region. West Pac Surveill Response. 2016 03 31;7(1):44–7. pmid:27757256 doi:10.5365/wpsar.2016.7.1.007